Residual estrogen receptor availability during fulvestrant 500 mg therapy in patients with metastatic breast cancer.
Michel van Kruchten
No relevant relationships to disclose
Elisabeth De Vries
No relevant relationships to disclose
Myles Brown
Research Funding - Novartis
Andor W. J. M. Glaudemans
No relevant relationships to disclose
Meta C. van Lanschot
No relevant relationships to disclose
Ido P. Kema
No relevant relationships to disclose
Martijn Van Faassen
No relevant relationships to disclose
Carolien P. Schroder
No relevant relationships to disclose
Erik F. J. De Vries
No relevant relationships to disclose
Geke Hospers
Research Funding - AstraZeneca